

Index

A

- ABCA1, knockout mouse, 284
- ABCA7, late-onset Alzheimer disease role, 254
- ACC-001, amyloid- β immunotherapy, 445
- ACE. *See* Angiotensin-converting enzyme
- Acetylcholine receptor
 - amyloid- β interactions, 195, 320
 - muscarinic agonist therapy, 485
 - nicotinic agonist therapy, 485
- Acetylcholinesterase, inhibitor therapy,
 - 476–480, 489
- Acylpeptide hydrolase (APH), amyloid- β degradation,
 - 396
- AD8, Alzheimer disease screening, 13–14
- ADAMs
 - ADAM10 and late-onset Alzheimer disease role,
 - 255–256
 - amyloid precursor protein processing, 210–211
- Aging
 - Alzheimer disease risks, 15
 - Alzheimer neuropathology in normal aging, 55–56
 - healthy cognitive aging, 10–11
- Agitation Inventory, 14
- α -Secretase. *See also* ADAMs
 - amyloid precursor protein processing, 210–211
 - subcellular sites of processing, 216
- AlzGene, late-onset Alzheimer disease variants, 253
- AMPA receptor, therapeutic targeting, 486
- Amyloid- β
 - aggregation
 - biophysics, 434–435
 - inhibitors
 - animal studies, 436–437
 - clinical studies, 437–438
 - in vitro studies, 435–436
 - prospects for study, 438
 - amyloid hypothesis of Alzheimer disease, 405–407
 - apolipoprotein E
 - interactions, 282–284
 - receptors
 - metabolism regulation, 290–291
 - synaptic suppression antagonism, 287–288
 - balance between production and clearance, 389–391
 - BAPTists versus TAUists, 5–6
 - biochemistry in deposits and plaques, 182–185
 - cerebrospinal fluid biomarker studies
 - isoforms, 92–95, 97, 100
 - oligomers, 97
 - soluble protein, 97
 - cognitive function disruption, 325, 327–328
 - diffusible oligomers
 - molecular dynamics, 188
 - natural oligomers, 188–190
 - overview, 186–187
 - recombinant oligomers, 188
 - synthetic A β as substrate for oligomer formation,
 - 187–188
 - fibril structure and properties, 185–186
 - forms in neuronal impairment, 318–319
 - history of study, 181–182
 - immunization therapy
 - active immunization
 - ACC-001, 445
 - AN1792 clinical trial, 441–443
 - CAD-106, 445
 - mechanism of action, 439–441, 464
 - overview, 438
 - preclinical observations, 439
 - passive immunization, 443–445
 - membrane interactions
 - electrostatic/charge effects, 194
 - hydrophobic interactions, 194
 - lipoprotein interactions, 194–195
 - phase/interface effects, 193–194
 - receptor interactions, 195
 - metal ion interactions, 191–193
 - plasma biomarkers, 102
 - positron emission tomography imaging
 - applications, 78–80
 - limitations, 80
 - principles, 77–78
 - production, 212
 - proteolytic degradation
 - environmental insults, 392
 - inhibitors, 398–399
 - irreversibility, 392
 - protease defining of amyloid- β pools,
 - 391–392
 - protease types
 - acylpeptide hydrolase, 396
 - angiotensin-converting enzyme, 395
 - BACE1, 397
 - BACE2, 397–398
 - catalytic antibodies, 398

Index

- Amyloid- β (*Continued*)
 - cathepsin B, 397
 - cathepsin D, 397
 - endothelin-converting enzymes, 394
 - insulin-degrading enzyme, 395–396
 - matrix metalloproteinases, 395
 - myelin basic protein, 396
 - neprilysin, 393–394
 - neprilysin-like peptidases, 394
 - overview, 392–393
 - plasmin, 396
 - proteasome, 398
 - regulation of amyloid- β levels, 388–389
 - sites, 392
 - therapeutic targeting, 399
 - synaptic function
 - early perturbations, 319
 - extracellular versus intraneuronal amyloid- β
 - effects, 324–325
 - oligomer receptors in perturbation, 322
 - synaptic depression enhancement, 321–322
 - synaptic transmission modulation, 319–321
 - therapeutic implications, 328–330
 - transgenic mouse models, 304
- Amyloid plaque
 - clinicopathological correlations, 51
 - composition, 48
 - definition, 44
 - morphology, 49
 - topographical distribution, 49–50
 - Amyloid precursor-like proteins (APLPs), γ -secretase processing, 264
 - Amyloid precursor protein (APP)
 - amyloid- β production, 212
 - apolipoprotein E receptor regulation of trafficking and processing, 289–290
 - apoptosis studies, 236
 - axonal transport, 233–234
 - cell and synaptic adhesion studies, 234
 - gene duplication, 373
 - gene family, 232
 - intracellular signaling, 236
 - isoforms
 - axon pruning and degeneration, 235
 - knockout studies, 239
 - loss of function studies
 - Caenorhabditis elegans*, 236–237
 - Drosophila*, 236–237
 - knockout mice
 - combined knockouts, 238
 - conditional knockouts, 239–240
 - single knockout, 237–238
 - proteases
 - BACE1, 207–208
 - α -secretase, 210–211
 - γ -secretase and presenelins, 208–210
 - proteolytic processing
 - activity-dependent processing, 219–222
 - degradation, 219
 - overview, 205–206, 232
 - subcellular sites of processing, 216, 218
 - structure, 232–233
 - subcellular localization, 233
 - tissue distribution, 233
 - trafficking
 - endocytic sorting, 211–212
 - neurons, 215–217
 - polarized trafficking
 - secretase sorting, 213, 215
 - sorting mechanisms, 212–214
 - trophic function, 234–235
 - variants in Alzheimer disease
 - early-onset familial Alzheimer disease, 251
 - overview, 123, 207
 - AN1792, clinical trial, 441–443
 - Angiotensin-converting enzyme (ACE), amyloid- β degradation, 395
 - Animal models, Alzheimer disease
 - clinical translation concerns, 309–312
 - knockout mice, 307–309
 - transgenic mice, 303–307
 - APH. *See* Acylpeptide hydrolase
 - APLPs. *See* Amyloid precursor-like proteins
 - APOE ϵ 4
 - Alzheimer disease risks, 15, 124, 281
 - positron emission tomography brain metabolism findings in Alzheimer disease, 76
 - Apolipoprotein E
 - amyloid- β interactions, 194–195, 282–284
 - late-onset Alzheimer disease variants, 252–253, 281–282
 - neurobiology, 281
 - receptors. *See also specific receptors*
 - amyloid- β -induced synaptic suppression antagonism, 287–288
 - amyloid- β metabolism regulation, 290–291
 - amyloid precursor protein trafficking and processing regulation, 289–290
 - LDLR1 functional overview, 291–293
 - LRP1 functional overview, 291–293
 - neuroprotection studies, 288–289
 - signaling, 285–286
 - synaptic plasticity studies, 284–287
 - Tau phosphorylation regulation, 286
 - types, 280–281
 - Apoptosis, amyloid precursor protein studies, 236
 - APP. *See* Amyloid precursor protein
 - Arachidonic acid, inflammation mediations, 345
 - Astrocyte
 - Alzheimer disease effects, 52
 - inflammation mediation, 339–340
 - Attention, Alzheimer disease deficits, 28

- ATXN1*, late-onset Alzheimer disease role, 253–254
Autophagic vacuole (AV), accumulation in neurons, 373
AV. *See* Autophagic vacuole
Axona (Ketasyn), Alzheimer disease treatment studies, 484–485, 488
- B**
- BACE1
amyloid- β degradation, 397
amyloid precursor protein processing, 207–208, 423–426
cerebrospinal fluid biomarker studies, 97
inhibitors, 431–433
knockout mouse, 308
polarized sorting, 213, 215
structure, 426, 432
subcellular sites of processing, 216, 218
- BACE2
amyloid- β degradation, 397–398
inhibitors, 431–433
- BBB. *See* Blood–brain barrier
Begacestat, presenelin inhibition, 270–271
Behavioral variant frontotemporal dementia. *See* Frontotemporal lobar degeneration
 β -Secretase. *See* BACE1
BIN1. *See* Bridging integrator 1
Biomarkers. *See* Cerebrospinal fluid; Plasma biomarkers
Blood–brain barrier (BBB), dysfunction in Alzheimer disease
GLUT1, 409
LRP, 410–413
overview, 409
RAGE, 410
vascular-specific gene expression, 413–414
BMS-708163, presenelin inhibition, 270–271, 430–431
Body weight, Alzheimer disease risk factor, 119
Bridging integrator 1 (BIN1), variants in Alzheimer disease, 123
- C**
- C9ORF72*, frontotemporal lobar degeneration mutations, 169–170
CAA. *See* Cerebral amyloid angiopathy
CAD-106, amyloid- β immunotherapy, 445
Cambridge Mental Disorders of the Elderly Examination, 14
Carbamazepine, agitation management in Alzheimer disease, 481
Cathepsin B, amyloid- β degradation, 397
Cathepsin D, amyloid- β degradation, 397
CBF. *See* Cerebral blood flow
CBS. *See* Corticobasal syndrome
CD2AP, late-onset Alzheimer disease role, 254
CD33, late-onset Alzheimer disease role, 253–254
CDK5, inhibitor therapy, 461
CDR. *See* Clinical Dementia Rating
CERAD Behavior Rating Scale for Dementia, 14
Cerebral amyloid angiopathy (CAA)
apolipoprotein E knockout mice, 283
clinicopathological correlations, 51–52
composition, 51
definition, 44
microvascular degeneration, 409
morphology, 51
topographical distribution, 51
Cerebral blood flow (CBF), Alzheimer disease findings, 408–409
Cerebrolysin, Alzheimer disease treatment studies, 483, 487
Cerebrospinal fluid (CSF), biomarkers for Alzheimer disease
amyloid- β
isoforms, 92–95, 97, 100
oligomers, 97
soluble protein, 97
BACE1, 97
clinical trial application
diagnosis/enrichment of Alzheimer disease cases, 103
drug response monitoring, 105–106
safety monitoring, 104–105
stratification of Alzheimer disease cases, 103–104
combination studies, 94, 106–107
diagnostic performance
Alzheimer disease with dementia, 94–95
autopsy-verified Alzheimer disease, 95
preclinical Alzheimer disease, 95–96
prodromal Alzheimer disease, 95
endophenotypes in genetic studies, 106
GAP-43, 100
inflammation and oxidative stress markers, 100–101
neurofilament proteins, 100
overview, 92–93, 98–99
prospects, 106–107
Stable Isotope Labeling Kinetics, 101–102
Tau
phosphorylation, 93–94
total protein, 92–93
visinin-like protein-1, 100
CHMP2B, frontotemporal lobar degeneration mutations, 171
Clinical Dementia Rating (CDR), 14
Clock Drawing test, 14
Clusterin
late-onset Alzheimer disease role, 254
variants in Alzheimer disease, 123
Cognitive enhancement, Alzheimer disease protection, 122–123

Index

- Cognitive reserve, Alzheimer disease protection, 120–121
- Complement, inflammation mediation, 341–343
- Complement receptor 1 (CR1), variants in Alzheimer disease, 123, 254
- Copper, amyloid- β interactions, 192–193
- Corticobasal syndrome (CBS)
clinical presentation, 162
histopathology, 163, 165
- COX. *See* Cyclooxygenase
- CR1. *See* Complement receptor 1
- CSE. *See* Cerebrospinal fluid
- Curcumin, Alzheimer disease treatment studies, 490
- CX-1837, Alzheimer disease treatment studies, 486
- Cyclooxygenase (COX)
inflammation mediation, 345
therapeutic targeting in Alzheimer disease, 347–348, 428, 487, 490
- D**
- Definite Alzheimer disease, diagnostic criteria, 11–12, 54
- Dementia
definition, 11
detection, 11, 13–14
- Dementia with Lewy bodies (DLB)
Alzheimer disease differential diagnosis, 18, 30–31
Lewy body ubiquitination, 363–364
overlap with Alzheimer disease, 56–57
- Dense-core plaque, definition, 44
- Depression
Alzheimer disease differential diagnosis, 19
antidepressants in Alzheimer disease, 481
- Diabetes type II, Alzheimer disease risk factor, 119
- Diffuse plaque, definition, 44
- Dimebon (Latrepidine), Alzheimer disease treatment studies, 487, 489
- DLB. *See* Dementia with Lewy bodies
- Docosahexaenoic acid (DHA), Alzheimer disease treatment studies, 483, 487
- Donepezil, acetylcholinesterase inhibition, 476, 478–479
- Down syndrome, 327
- E**
- E2012, presenelin inhibition, 430
- Early-onset familial Alzheimer disease (EO-FAD), genetics, 249–252, 497
- ECs. *See* Endothelin-converting enzymes
- Economic impact, Alzheimer disease, 9
- EHT0202. *See* Etazolate
- ELND006, presenelin inhibition, 431
- Endothelin-converting enzymes (ECs), amyloid- β degradation, 394
- EO-FAD. *See* Early-onset familial Alzheimer disease
- EPHA1, late-onset Alzheimer disease role, 254
- Epidemiology, Alzheimer disease
definitions and criteria, 115–116
genetic epidemiology
common variants, 124
late-onset Alzheimer disease, 124
rare variants, 123–124
incidence, 9, 116–117
inflammation, 346–347t
prevalence, 9, 116–117
protective factors
cognitive enhancement, 122–123
cognitive reserve, 120–121
diet, 121–122
exercise, 122
risk factors
body weight, 119
cerebrovascular disease, 118
diabetes type II, 119
hypertension, 118–119
smoking, 119–120
traumatic brain injury, 120
risk stratification and treatment, 500
- Episodic memory, Alzheimer disease deficits, 26–27
- Epothilone D, microtubule stabilization in Alzheimer disease, 460
- ERT. *See* Estrogen replacement therapy
- Estrogen replacement therapy (ERT), Alzheimer disease treatment studies, 487, 490
- Etazolate (EHT0202), Alzheimer disease treatment studies, 486
- Executive function, Alzheimer disease deficits, 28–29
- Exercise, Alzheimer disease protection, 122
- F**
- Fluorodeoxyglucose. *See* Positron emission tomography
- Flurbiprofen, presenelin inhibition, 428–429
- fMRI. *See* Functional magnetic resonance imaging
- Folic acid, Alzheimer disease treatment studies, 484
- Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17)
clinical presentation, 163
histopathology, 166
Tau mutations, 457
- Frontotemporal lobar degeneration (FTLD)
Alzheimer disease
differential diagnosis, 18–19, 31–32
overlap, 171–173
behavioral variant and Alzheimer disease differential diagnosis, 32–33, 35
clinical presentation
behavioral variant, 161
corticobasal syndrome, 162
logopenic progressive aphasia, 162

- motor neuron disease, 163
 - progressive nonfluent aphasia, 161–162
 - progressive supranuclear palsy, 162–163
 - semantic dementia, 161
 - gene mutations
 - C9ORF72*, 169–170
 - CHMP2B*, 171
 - FUS*, 170
 - MAPT*, 164, 169
 - TARDBP*, 170
 - VCP*, 170–171
 - histopathology
 - FTLD-FUS, 168
 - FTLD-Tau, 163–167
 - FTLD-TDP, 167–168
 - FTLD-UPS, 168
 - history of study, 159–161
 - FTDP-17. *See* Frontotemporal dementia and Parkinsonism linked to chromosome 17
 - FTLD. *See* Frontotemporal lobar degeneration
 - Functional magnetic resonance imaging (fMRI)
 - Alzheimer disease studies, 72–74
 - principles, 72
 - FUS*
 - frontotemporal lobar degeneration mutations, 170
 - FTLD-FUS, 168
 - Fyn, Tau interactions, 148
- G**
- Galantamine, acetylcholinesterase inhibition, 479
 - γ -Secretase. *See also* Nicastrin; *PEN2*; Presenelins
 - amyloid precursor protein processing, 208–210, 423–426
 - inhibitors, 269–271, 426–431
 - membrane topology, 262
 - Notch signaling, 269
 - stoichiometry of complex, 262
 - structure, 425
 - structure-function relationships, 265–266
 - subcellular sites of processing, 218–219
 - Gantenerumab, clinical trials, 445
 - GAP-43, cerebrospinal fluid biomarker studies, 100
 - GDS. *See* Geriatric Depression Scale; Global Deterioration Scale
 - General Practitioner Assessment of Cognition (GPCOG), 14
 - Geriatric Depression Scale (GDS), 14
 - Ginkgo biloba*, Alzheimer disease treatment studies, 482, 488
 - Global Deterioration Scale (GDS), 14
 - GLUT1, blood–brain barrier dysfunction in Alzheimer disease, 409
 - Glycogen synthase kinase 3 β (GSK3 β)
 - apolipoprotein E receptor signaling, 285
 - inhibitor therapy, 461
 - GPCOG. *See* General Practitioner Assessment of Cognition
 - Granovacuolar degeneration (GVD), 52
 - Growth hormone, Alzheimer disease treatment studies, 487
 - GSK3 β . *See* Glycogen synthase kinase 3 β
 - GSK933776A, clinical trials, 445
 - GVD. *See* Granovacuolar degeneration
- H**
- Heat shock protein-70 (HSP70), Tau binding with CHIP, 463
 - Heat shock protein-90 (HSP90), therapeutic targeting, 463
 - Hippocampus, amyloid- β effects, 327, 329
 - Hirano bodies, 52
 - Histamine receptor, H3 antagonist therapy, 486
 - Homocysteine, levels in Alzheimer disease, 483–484
 - Homotaurine, Alzheimer disease treatment studies, 484
 - HSP70. *See* Heat shock protein-70
 - HSP90. *See* Heat shock protein-90
 - Huperzine A, Alzheimer disease treatment studies, 483
 - Hypertension, Alzheimer disease risk factor, 118–119
- I**
- IDE. *See* Insulin-degrading enzyme
 - Idebenone, Alzheimer disease treatment studies, 488
 - Incidence. *See* Epidemiology, Alzheimer disease
 - Inflammation
 - Alzheimer disease studies
 - epidemiology, 346–347
 - gene polymorphisms in inflammation pathways, 345–346
 - prevention trials, 348
 - prospects for study, 348–349, 499
 - treatment trials, 347–348
 - arachidonic acid, 345
 - cellular mediators
 - astrocyte, 339–340
 - microglia, 336–339
 - neuron, 340–341
 - oligodendrocyte, 340
 - cerebrospinal fluid biomarkers for Alzheimer disease, 100–101
 - complement system, 341–343
 - cyclooxygenase, 345
 - cytokines and chemokines, 343–344
 - Toll-like receptors, 344–345
 - Insulin, Alzheimer disease treatment studies, 486–487

Index

Insulin-degrading enzyme (IDE), amyloid- β
degradation, 395–396
Iron, amyloid- β interactions, 193

K

Ketasyn. *See* Axona

L

Language, Alzheimer disease deficits, 27
Late-onset Alzheimer disease (LOAD), genetics
AlzGene, 253
APOE, 252–253
genome-wide association studies, 253–255
overview, 124
Latrepidine. *See* Dimebon
LDLR1
amyloid- β metabolism regulation, 290–291
amyloid precursor protein trafficking and processing
regulation, 289–290
functional overview, 291–293
Leuprolide, Alzheimer disease treatment studies, 488
Lewy body. *See* Dementia with Lewy bodies
Lithium chloride, Tau phosphorylation inhibition
therapy, 461, 464, 487
LOAD. *See* Late-onset Alzheimer disease
Logopenic progressive aphasia (LPA)
clinical presentation, 162
histopathology, 163
Long-term depression (LTD)
amyloid- β oligomer enhancement, 322–324
lysosomal network defects in induction, 376
LPA. *See* Logopenic progressive aphasia
LRP1
amyloid- β metabolism regulation, 290–291
amyloid precursor protein trafficking and processing
regulation, 289–290
blood–brain barrier dysfunction in Alzheimer
disease, 410–413
functional overview, 291–293
knockout mouse, 286
LTD. *See* Long-term depression
LY450139. *See* Semagacestat
LY451395, Alzheimer disease treatment
studies, 486
LY2062430, clinical trials, 444–445
LY2811376, BACE inhibition, 432–434
Lysosomal network
Alzheimer disease role
genetic findings, 373–375
molecular pathology, 371–373
neuritic dystrophy, 375
neurodegeneration, 377
protein clearance failure and amyloidogenesis,
375–376

synaptic dysfunction, 376–377
tauopathy, 376
overview, 359–361, 369–371
therapeutic targeting, 377–378

M

Magnetic resonance imaging (MRI). *See also* Functional
magnetic resonance imaging
diffusion tensor imaging, 80
initial assessment of dementia, 15
principles, 68–69
structural imaging in Alzheimer disease
advantages, 21
atrophy, 69–70
gross features, 45
limitations, 21
progression studies, 70–71
MAPT
early-onset familial Alzheimer disease
mutations, 251
frontotemporal lobar degeneration mutations,
164, 169
Matrix metalloproteinases (MMPs), amyloid- β
degradation, 395
MBP. *See* Myelin basic protein
MCI. *See* Mild cognitive impairment
Memantine, NMDA receptor antagonism and therapy,
480–481
MEOX2, expression in Alzheimer disease, 413–414
Methylene blue, Tau fibrillization inhibition,
466–467
Microglia, inflammation mediation, 336–339
Microglia, Alzheimer disease effects, 52
Mild Alzheimer disease
clinical presentation, 16
neuropathology, 54–55
Mild cognitive impairment (MCI)
diagnostic criteria, 19–20
neuropathology, 54–55
nonsteroidal anti-inflammatory drug prevention
trials, 348
Mini-Mental Status Examination (MMSE), 14, 100,
429, 475
MK-0752, presenelin inhibition, 428
MMPs. *See* Matrix metalloproteinases
MMSE. *See* Mini-Mental Status Examination
MND. *See* Motor neuron disease
Moderate Alzheimer disease, clinical presentation,
16–17
Mortality, Alzheimer disease, 10, 16
Motor neuron disease (MND), frontotemporal
dementia, 163, 170
MRI. *See* Magnetic resonance imaging
MSA6A/MSA4E, late-onset Alzheimer
disease role, 254

- Myelin basic protein (MBP), amyloid- β degradation, 396
- Myocardin, expression in Alzheimer disease, 413–414
- N**
- NAP, microtubule stabilization in Alzheimer disease, 460
- Nephrilysin, 393–394
- Nerve growth factor (NGF), gene therapy, 488, 490–491
- Neurofibrillary tangles (NFTs)
- animal models, 305–306
 - clinicopathological correlations, 47–48
 - composition, 46
 - definition, 44
 - lysosomal network defects in tauopathy, 376
 - morphology, 46–47
 - topographical distribution, 47
 - ubiquitination, 365–366
- Neurofilament proteins, cerebrospinal fluid biomarker studies, 100
- Neuron, loss in Alzheimer disease, 52–53
- Neuropil thread, definition, 44
- Neuropsychiatric Inventory (NPI), 14, 477
- Neurovascular unit (NVU), components and dysfunction in Alzheimer disease, 407–408
- NFTs. *See* Neurofibrillary tangles
- NGF. *See* Nerve growth factor
- Nicestrin, 261
- NMDA receptor. *See* N-Methyl-D-aspartate receptor
- N-Methyl-D-aspartate (NMDA) receptor
- amyloid- β interactions, 195
 - amyloid precursor protein level effects, 220
 - dimebon antagonism, 489
 - memantine antagonism and therapy, 480–481
 - reelin effects, 287
- Notch, γ -secretase
- signaling, 269
 - sparing inhibitors, 270–271, 430
- NPI. *See* Neuropsychiatric Inventory
- NVU. *See* Neurovascular unit
- O**
- Oligodendrocyte, inflammation mediation, 340
- Omega-3 fatty acids, Alzheimer disease
- protection, 121
- P**
- Paired helical filament (PHF)
- Tau structure, 138–140
 - ubiquitin discovery, 361–363
- Parkinson's disease (PD), dementia overlap with Alzheimer disease, 56
- Pathological criteria, Alzheimer disease diagnosis, 53–54
- PAXIP1*, early-onset familial Alzheimer disease mutations, 251
- PCA. *See* Posterior cortical atrophy
- PD. *See* Parkinson's disease
- PDE. *See* Phosphodiesterase
- PEN2*, early-onset familial Alzheimer disease mutations, 251
- Peroxisome proliferator-activated receptor- γ (PPAR- γ), agonist therapy, 486–487, 489
- PET. *See* Positron emission tomography
- PF-03084014, presenelin inhibition, 428
- PHF. *See* Paired helical filament
- Phosphatidylinositol-binding clathrin assembly protein (PICALM), variants in Alzheimer disease, 123, 254
- Phosphodiesterase (PDE), inhibitor therapy, 486
- PiB. *See* Pittsburgh Compound-B
- PICALM. *See* Phosphatidylinositol-binding clathrin assembly protein
- Pin1, Tau interactions, 148
- Pioglitazone, Alzheimer disease treatment studies, 486
- Pittsburgh Compound-B (PiB), 76, 92, 444
- Plasma biomarkers, Alzheimer disease, 102–103
- Plasmin, amyloid- β degradation, 396
- PNFA. *See* Progressive nonfluent aphasia
- Positron emission tomography (PET)
- amyloid studies
 - applications, 78–80
 - limitations, 80
 - principles, 77–78 - fluorodeoxyglucose studies of Alzheimer disease
 - biomarker utility, 76–77
 - hypometabolism pattern, 75–76
 - limitations, 77
 - overview, 15
 - principles, 74–75
- Possible Alzheimer disease, diagnostic criteria, 11–13, 54
- Posterior cortical atrophy (PCA), Alzheimer disease pathology, 29–30
- PPA. *See* Primary progressive aphasia
- PP2A. *See* Protein phosphatase 2A
- PPAR- γ . *See* Peroxisome proliferator-activated receptor- γ
- Pravastatin, Alzheimer disease treatment studies, 489
- Prednisone, Alzheimer disease trials, 348
- Presenelins
- amyloid precursor protein processing, 208–210
 - early-onset familial Alzheimer disease
 - PSEN1* mutations, 250–251
 - PSEN2* mutations, 251 - functional overview, 262–265
 - genes, 260
 - inhibitors, 269–271, 307, 269–271, 426–431

Index

- Presenelins (*Continued*)
 knockout mice, 307
 Notch signaling, 269
 processing, 261
 structure, 260
 structure-function relationships, 265–267
 variants in Alzheimer disease, 123, 266, 268
- Prevalence. *See* Epidemiology, Alzheimer disease
- Primary progressive aphasia (PPA), Alzheimer disease
 differential diagnosis, 32–33, 35
- Probable Alzheimer disease, diagnostic criteria,
 11–13, 54
- Progressive nonfluent aphasia (PNFA)
 clinical presentation, 161–162
 histopathology, 163
- Progressive supranuclear palsy (PSP)
 clinical presentation, 162–163
 histopathology, 163, 165
- Proteasome. *See* Ubiquitin–proteasome system
- Protein phosphatase 2A (PP2A), therapeutic targeting,
 462
- PSP. *See* Progressive supranuclear palsy
- R**
- RAGE. *See* Receptor for advanced glycation end products
- Receptor for advanced glycation end products (RAGE)
 Alzheimer disease role, 344–345
 blood–brain barrier dysfunction in Alzheimer
 disease, 410
 therapeutic targeting, 490
- Reelin, apolipoprotein E receptor signaling, 285–287
- Research driving forces, Alzheimer disease
 competition of ideas and findings, 5–6
 personal tragedy, 4
 quest for scientific clarity, 3–4
 societal crisis, 4–5
- Resveratrol, Alzheimer disease treatment studies, 488,
 491
- Risk factors. *See* Epidemiology, Alzheimer disease
- Rivastigmine, acetylcholinesterase inhibition, 476,
 478–479
- Rosiglitazone, Alzheimer disease treatment studies,
 486–487
- S**
- SBT. *See* Short Blessed Test
- scyllo*-Inositol, amyloid- β aggregation inhibition,
 437–438
- SD. *See* Semantic dementia
- Semagacestat (LY450139), presenelin inhibition,
 269–270, 427
- Semantic dementia (SD)
 clinical presentation, 161
 histopathology, 163
- Semantic memory, Alzheimer disease deficits, 27–28
- Serum response factor (SRF), expression in Alzheimer
 disease, 413–414
- Seven-Minute Screen, 14
- Severe Alzheimer disease, clinical presentation, 16–17
- Short Blessed Test (SBT), 14
- SILK. *See* Stable Isotope Labeling Kinetics
- Smoking, Alzheimer disease risk factor, 119–120
- SORL1*, variants in Alzheimer disease, 123–124
- SorLA/LR1, amyloid- β production regulation, 212
- Souvenaid, Alzheimer disease treatment studies, 485, 488
- SRF. *See* Serum response factor
- Stable Isotope Labeling Kinetics (SILK), cerebrospinal
 fluid biomarker studies, 101–102
- Statins, Alzheimer disease treatment studies, 487, 489
- Stroke, Alzheimer disease risk factor, 118
- Synapse, loss in Alzheimer disease, 53
- T**
- TARDBP*, frontotemporal lobar degeneration
 mutations, 170
- Tarenflurbil, presenelin inhibition, 270, 428, 430
- Tau
 acetylation, 418, 462
 aggregation, 143
 Alzheimer disease pathology, 140–143
 BAPTists versus TAUists, 5–6
 binding partners, 145–149
 cerebrospinal fluid biomarker studies
 phosphorylation, 93–94
 total protein, 92–93
 degradation regulation, 369
 distribution, 143–145
 domains, 134–135
 frontotemporal lobar degeneration histopathology,
 163–167
 FTDP-17 mutations, 457
 gene. *See* *MAPT*
 glycosylation, 142, 457, 462
 history of study, 133–134
 immunization therapy, 464–465
 isoforms, 135, 456
 lysosomal network defects in tauopathy, 376
 microtubule binding, 455–456
 microtubule interactions, 136–138, 141, 147
 paired helical filament structure, 138–140
 phosphorylation
 inhibitors, 460–463
 overview, 141–142
 regulation by apolipoprotein E receptor, 286
 proteolysis, 142
 structure, 135–136
 ubiquitination, 363–364
- TDP43
 FTLD-TDP, 167–168, 170

- therapeutic targeting
 - challenges, 457–458
 - degradation enhancement, 463–465
 - fibrillization inhibition, 466–467
 - loss-of-function compensation, 459–460
 - phosphorylation inhibitors, 460–463
 - strategies, 458–459
 - Tetrodotoxin (TTX), amyloid precursor protein secretion effects, 220–222
 - Thioflavin T, amyloid- β aggregation studies, 435
 - TLRs. *See* Toll-like receptors
 - Toll-like receptors (TLRs), inflammation mediation, 344–345
 - Tramipolate, amyloid- β aggregation inhibition, 436–437
 - Traumatic brain injury, Alzheimer disease risk factor, 120
 - TTX. *See* Tetrodotoxin
- U**
- Ubiquitin–proteasome system
 - Alzheimer disease role, 367–369
 - amyloid- β degradation, 398
 - FTLD-UPS, 168
 - neurofibrillary tangle ubiquitination, 365–366
 - overview, 359–361
 - paired helical filament ubiquitin, 361–363
 - Tau ubiquitination, 363–364
 - ubiquitination steps, 366
- V**
- VaD. *See* Vascular dementia
 - Valproic acid, Alzheimer disease treatment studies, 487
 - Vascular dementia (VaD), Alzheimer disease differential diagnosis, 17–18, 33–34, 36
 - VCP, frontotemporal lobar degeneration mutations, 170–171
 - Visinin-like protein-1, cerebrospinal fluid biomarker studies, 100
 - Visuospatial ability, Alzheimer disease deficits, 29–30
 - Vitamin B₆, Alzheimer disease treatment studies, 484
 - Vitamin D Alzheimer disease protection, 121
 - Vitamin E, Alzheimer disease treatment studies, 484, 488
- W**
- Working memory, Alzheimer disease deficits, 28
- X**
- Xaliproden, Alzheimer disease treatment studies, 488
- Z**
- Zinc, amyloid- β interactions, 193